Introduction
IBD pipeline products are set to challenge Remicade and other existing
therapies in the management of the disease. Competition will intensify as
CDP870, Antegren, and Humira provide new alternatives in the severe Crohn's
disease market, and mode of administration will be a key element of product
differentiation. In ulcerative colitis, drugs with novel mechanisms will compete
for patient share.
Scope of this report
- Assessment of epidemiological data and patient potential
- Analysis of IBD product pipeline with emphasis on Phase III, including
trial results and opinion leader insight
- Seven country sales forecasts to 2014
- Transcripts of interviews with key IBD opinion leaders in the US, UK, and
Japan
Research and analysis highlights
Antegren has been filed early for multiple sclerosis on the basis of one year
data from Phase III studies. Strong uptake of Antegren in multiple sclerosis,
followed by approval for Crohn's disease in 2006, will put pressure on Biogen
Idec's manufacturing capabilities, making swift completion of a new production
plant in San Diego crucial.
Patients who received a limited course of induction therapy with Remicade in
effect were "immunized" against the product, and sometimes have not
been able to benefit from maintenance therapy when this indication has been
approved. This has shrunk the potential patient population for Remicade in
Crohn's disease, reducing revenues.
A desire to stay with "tried and trusted" Remicade means that in
Crohn's disease, switching from Remicade caused by Medicare drug coverage in
2006 will be limited. Uptake of CDP870, Antegren, and Humira in Crohn's disease
will be boosted by Medicare reform, but probably not at Remicade's expense.
Key reasons to read this report
- Understand the impact of Medicare reform in the biologics for IBD market
and how companies are positioning products for maximum benefit
- In a sector heavily dependent on licensing deals, appreciate why big
pharma needs to worry about alienating potential partners
- Explore IBD clinical trial design and recruitment strategies to understand
how to maximize chances for success
View Cart
